6 Analysts Have This to Say About Biomarin Pharmaceutical
Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Wedbush Maintains Neutral on Biomarin Pharmaceutical, Raises Price Target to $83
Wedbush analyst Andreas Argyrides maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and raises the price target from $74 to $83.
BioMarin Announced Stable and Durable Annualized Bleed Control for ROCTAVIAN in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; Said 92% of Patients off Prophylaxis at the End of Year 3
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive results from more than three years of follow up from its ongoing global Phase 3 GENEr8-1 study of ROCTAVIANTM (valoctocogene roxaparvovec), an investigational one-time gene therapy for the treatment of adults with severe hemophilia A.
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Otonomy (NASDAQ:OTIC) shares increased by 19.1% to $0.21 during Thursday’s pre-market session. The company’s market cap stands…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Expert Ratings for Biomarin Pharmaceutical
Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter: Bullish Somewhat Bullish Indifferent…
Jefferies Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $120
Jefferies analyst Akash Tewari maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $100 to $120.
Canceled AdCom, UniQure’s Hemgenix Approval Show Positive Signs For BioMarin’s Hemophilia Candidate
Earlier today, the FDA notified BioMarin Pharmaceutical Inc (NASDAQ:BMRN) that the agency no longer plans to hold an advisory committee meeting to…
BioMarin Announces Incremental Progress On Biologics License Application Review For Valoctocogene Roxaparvovec AAV Gene Therapy For Adults With Severe Hemophilia A Program
FDA Pre-Licensure Inspection of Gene Therapy Manufacturing Facility Scheduled
FDA Requests Submission of Upcoming 3-Year Data Analysis from Phase 3 GENEr8-1 Study
Current PDUFA Target Action Date of March 31, 2023,
